Biodesix Inc., a leader in personalized diagnostics, announced that it played a crucial role in the validation of Thermo Fisher's Oncomine Dx Express Test, leading to the FDA approval of the Genexus Dx Integrated Sequencer. As part of this achievement, Biodesix has been recognized as a Thermo Fisher Scientific Center of Excellence $(COE)$ for NGS Diagnostics. This recognition is part of Thermo Fisher's initiative to advance NGS-based diagnostics. The collaboration highlights Biodesix's commitment to enhancing molecular diagnostic and NGS testing capabilities, particularly in the field of oncology, and positions the company as a key player in transforming cancer diagnosis and care. There is no mention of a grant or funding obtained by multiple organizations in the provided context.